Key Takeaways ABBV stock rose 8% in six months, gaining over $24B in market cap as investors respond to post-Humira growth. Skyrizi and Rinvoq brought in$5.1B in Q1 2025 sales, up 65%, with $31B projected by 2027. ABBV pipeline gains from 20 recent deals and a push into oncology, neuroscience and obesity therapies.AbbVie (ABBV) stock has risen 8.0$24 billion to its market value.AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Hum ...